Nurix Therapeutics, Inc. (NRIX)

12.78 +0.05 (+0.39%) At close: 04:00PM EDT

Nurix Therapeutics, Inc.

1700 Owens Street
Suite 205
San Francisco, CA 94158
United States
415 660 5320
https://www.nurixtx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 284

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Arthur T. Sands M.D., Ph.D.	CEO, President & Director	986.32k	N/A	1962
Mr. Johannes Van Houte	Chief Financial Officer	681.98k	N/A	1966
Dr. Gwenn M. Hansen Ph.D.	Chief Scientific Officer	702.75k	N/A	1971
Dr. John Kuriyan Ph.D.	Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Mr. Michael Rapé Ph.D.	Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Dr. Arthur Weiss M.D., Ph.D.	Founder & Member of Scientific Advisory Board	N/A	N/A	N/A
Rita Kwong	Senior Accounting Manager	N/A	N/A	N/A
Dr. Christine Ring J.D., Ph.D.	Chief Legal Officer, Secretary & Chief Compliance Officer	595.83k	599.89k	1965
Mr. Eric C. Schlezinger J.D.	Chief People Officer	N/A	N/A	1967
Dr. Jason Kantor Ph.D.	Chief Business Officer	N/A	N/A	N/A

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Corporate Governance

Nurix Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 7. The pillar scores are Audit: 7; Board: 6; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.